479 related articles for article (PubMed ID: 21386762)
1. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
[TBL] [Abstract][Full Text] [Related]
2. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
Lai TY; Lee GK; Luk FO; Lam DS
Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
[TBL] [Abstract][Full Text] [Related]
4. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Maruko I; Iida T; Sugano Y; Saito M; Sekiryu T
Am J Ophthalmol; 2011 Apr; 151(4):594-603.e1. PubMed ID: 21295766
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID
Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458
[TBL] [Abstract][Full Text] [Related]
6. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1272-9. PubMed ID: 22547209
[TBL] [Abstract][Full Text] [Related]
7. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
[TBL] [Abstract][Full Text] [Related]
8. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Song MH; Ryu HW; Roh YJ
Ophthalmologica; 2011; 226(3):119-26. PubMed ID: 21757883
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
Kim SJ; Yu HG
Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
[TBL] [Abstract][Full Text] [Related]
10. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.
Saito M; Iida T; Kano M
Retina; 2011 Sep; 31(8):1589-97. PubMed ID: 21654347
[TBL] [Abstract][Full Text] [Related]
12. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
13. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up.
Leal S; Silva R; Figueira J; Cachulo ML; Pires I; de Abreu JR; Cunha-Vaz JG
Retina; 2010 Sep; 30(8):1197-205. PubMed ID: 20827139
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
[TBL] [Abstract][Full Text] [Related]
17. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.
Oishi A; Kojima H; Mandai M; Honda S; Matsuoka T; Oh H; Kita M; Nagai T; Fujihara M; Bessho N; Uenishi M; Kurimoto Y; Negi A
Am J Ophthalmol; 2013 Oct; 156(4):644-51. PubMed ID: 23876867
[TBL] [Abstract][Full Text] [Related]
19. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
[TBL] [Abstract][Full Text] [Related]
20. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Kim M; Kim K; Kim DG; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
